TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28414548

Group type: EXPERIMENTAL
Intervention: Pathogen disgust condition
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Moral disgust condition
Number of subjects: 211

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Study 2 (Independent sample of community adults, N = 121)
Number of subjects: 211
Study: 27161750

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study: 24356166

Group type: EXPERIMENTAL
Intervention: Single-shot spinal (SSS) technique
Number of subjects: 44

Group type: COMPARATOR
Intervention: Combined spinal-epidural (CSE) technique
Number of subjects: 44
Study: 22567742

Group type: EXPERIMENTAL
Intervention: Leucovorin Sodium (LV/Na) with irinotecan or oxaliplatin combined with infusional 5-FU
Number of subjects: 57

Group type: COMPARATOR
Intervention: Leucovorin Calcium (LV/Ca) with irinotecan or oxaliplatin combined with infusional 5-FU
Number of subjects: 57
Study: 20597110

Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg plus methotrexate (MTX) during the 4-month open-label period (period A)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Abatacept (plus MTX)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (plus MTX)
Number of subjects: 190
Study: 17600622

Group type: EXPERIMENTAL
Intervention: Modafinil treatment for 2 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pre-treatment scan
Number of subjects: 8
Study: 15764868

Group type: EXPERIMENTAL
Intervention: Propranolol (mean achieved dose 106 +/- 38 mg/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12589349

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10606310

Group type: EXPERIMENTAL
Intervention: Magnesium citrate with X-prep and clear liquid diet for 2 days (group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dulcolax for 2 days and Fleet enema without dietary restriction (group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Golytely 20 ml/kg (up to 1 L) per hour for 4 h with clear liquid diet for 1 day (group C)
Number of subjects: 70
Study: 8606813

Group type: EXPERIMENTAL
Intervention: Digoxin (0.5 mg/daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2006519

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 750 mg p.o. b.i.d.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7152771

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body weight)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6431741

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate eye drops
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30654837

Group type: EXPERIMENTAL
Intervention: Temporary transvenous diaphragm pacing (TTVDP)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 88
Study: 28532339

Group type: EXPERIMENTAL
Intervention: Internet‐based physical activity intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 55
Study: 26899019

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 1209
Study: 24971787

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 68
Study: 22608107

Group type: EXPERIMENTAL
Intervention: Fimasartan 180 mg once daily for 4 weeks (study 1)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg once daily for 8 weeks (study 2)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg once daily for 8 weeks (study 2)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Fimasartan 240 mg once daily for 8 weeks (study 2)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg once daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Fimasartan (various doses)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 20573633

Group type: EXPERIMENTAL
Intervention: isoflurane-sufentanil (n = 51)
Number of subjects: 100

Group type: COMPARATOR
Intervention: propofol-sufentanil (n = 49)
Number of subjects: 100
Study: 18095196

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (5 mg/kg bolus and 500 mg/h for 24 hours)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline control (same volume as magnesium group)
Number of subjects: 70
Study: 16098397

Group type: EXPERIMENTAL
Intervention: Constant workload training (Group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Progressive/increasing workload training (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No training (Group C)
Number of subjects: 42
Study: 12552334

Group type: EXPERIMENTAL
Intervention: rCBF(k2*)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rCBF(K1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PR(k2*)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PR(K1)
Number of subjects: 20
Study: 10655909

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (kallikrein inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol and its lipid solvent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipid solvent (injected before propofol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipid solvent (injected twice)
Number of subjects: 0
Study: 8909621

Group type: EXPERIMENTAL
Intervention: Students for Peace intervention (comprehensive violence-prevention program)
Number of subjects: 8865

Group type: COMPARATOR
Intervention: Control group (district's usual care of violence prevention activities)
Number of subjects: 8865
Study: 1874199

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg kg‐1 (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam 0.6 mg kg‐1 (Group 2)
Number of subjects: 30
Study: 6191948

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg methylphenidate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (0 mg/kg methylphenidate)
Number of subjects: 41
Study: 29570173

Group type: EXPERIMENTAL
Intervention: Elemental liquid diet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Commercial semisolid diet
Number of subjects: 26
Study: 28079638

Group type: EXPERIMENTAL
Intervention: Preshaved axilla
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prewaxed axilla
Number of subjects: 20
Study: 25376639

Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 281
Study: 25540089

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (MCI) consisting of a self-management/education program of six meetings, including e-Health interventions, followed for 12 months.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (MCI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 100
Study: 22806681

Group type: EXPERIMENTAL
Intervention: T12/PR48
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: lead-in T12/PR48
Number of subjects: 662

Group type: COMPARATOR
Intervention: PR48 (placebo)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: telaprevir treatment
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: non-SVR patients
Number of subjects: 662
Study: 19884596

Group type: EXPERIMENTAL
Intervention: Educational intervention from nursery discharge until age 3 years
Number of subjects: 985

Group type: COMPARATOR
Intervention: Nonintervention (NI)
Number of subjects: 985
Study: 17323793

Group type: EXPERIMENTAL
Intervention: Deximune soft‐gelatin capsules (200 mg CsA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sandimmune Neoral (200 mg CsA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations (Deximune and Sandimmune)
Number of subjects: 24
Study: 15172146

Group type: EXPERIMENTAL
Intervention: Thermoluminescent dosimeters (TLD) used for in vivo dosimetry
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: TLD measurements
Number of subjects: 429
Study: 11597376

Group type: EXPERIMENTAL
Intervention: Topical GM-CSF mouthwashes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Combined topical use of antiseptic agent (povidone-iodine) and amphotericin B (AA)
Number of subjects: 31
Study: 10599595

Group type: EXPERIMENTAL
Intervention: Leukocyte reducing filter (LRF) added to FKDB
Number of subjects: 23

Group type: COMPARATOR
Intervention: Filtered knee drain blood (FKDB) without LRF
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: FKDB with resuspended erythrocytes
Number of subjects: 23
Study: 8573016

Group type: EXPERIMENTAL
Intervention: Zone I eyes
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Transitional eyes
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Zone II eyes
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Presence of prominent iris vessels at 34 to 35 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Degree of early retinal vessel development
Number of subjects: 3
Study: 1743806

Group type: EXPERIMENTAL
Intervention: 30 mg Parlodel-SRO administered in two intakes (b.i.d.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 30 mg Parlodel-SRO administered in one dose (once daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 30 mg Parlodel-SRO administered in three intakes (t.i.d.)
Number of subjects: 18
Study: 6174865

Group type: COMPARATOR
Intervention: MOPP alone (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MOPP alternating with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 75

Group type: COMPARATOR
Intervention: MOPP alone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MOPP plus ABVD
Number of subjects: 75
Study: 31027422

Group type: EXPERIMENTAL
Intervention: Memantine extended release treatment in MEM‐MD‐91 trial
Number of subjects: 517

Group type: COMPARATOR
Intervention: Memantine extended release treatment in MEM‐MD‐68 trial
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Memantine extended release treatment in MEM‐MD‐69 trial
Number of subjects: 517
Study: 30012391

Group type: EXPERIMENTAL
Intervention: Thai instrumental folk music listening
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 27618090

Group type: COMPARATOR
Intervention: Healthy diet group (n = 79)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: 50 g-oats group (n = 80)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: 100 g-oats group (n = 79)
Number of subjects: 298
Study: 24006148

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 0
Study: 23328283

Group type: EXPERIMENTAL
Intervention: Lactulose plus live combined Bacillus subtilis and Enterococcus faecium capsules for 14 days, followed by only Bacillus subtilis and Enterococcus faecium capsules for 14 days
Number of subjects: 216

Group type: COMPARATOR
Intervention: Lactulose plus placebo for 2 weeks, followed by only placebo for 2 weeks
Number of subjects: 216
Study: 19810663

Group type: EXPERIMENTAL
Intervention: WFG LASIK
Number of subjects: 11

Group type: COMPARATOR
Intervention: WFG PRK
Number of subjects: 11
Study: 18060813

Group type: EXPERIMENTAL
Intervention: Pregabalin therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Extended patient counseling
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard patient counseling
Number of subjects: 98
Study: 16044668

Group type: EXPERIMENTAL
Intervention: Talnetant (SB‐223412)
Number of subjects: 0
Study: 12848716

Group type: EXPERIMENTAL
Intervention: Periotest readings
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional special tests (mobility testing, percussion sounds, radiographs)
Number of subjects: 101
Study: 10097992

Group type: EXPERIMENTAL
Intervention: High-functioning autistic adults
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal adults (control group)
Number of subjects: 10
Study: 8630669

Group type: EXPERIMENTAL
Intervention: Pravastatin with CCBs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin without CCBs
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCBs
Number of subjects: 0
Study: 1360337

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 40
Study: 6200129

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cardio‐Conray
Number of subjects: 40
Study: 30053159

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) at 4.5 mg/m2/day in EXIST-1 and 10 mg/day in EXIST-2
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE)
Number of subjects: 223
Study: 29924641

Group type: EXPERIMENTAL
Intervention: 34G × 3.5 mm needle
Number of subjects: 77

Group type: COMPARATOR
Intervention: 32G × 4 mm needle
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Comparison of both needles
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 77
Study: 27502818

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo group)
Number of subjects: 0
Study: 25172950

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 nmol l(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21358707

Group type: EXPERIMENTAL
Intervention: Citalopram (selective serotonin-uptake inhibitor) administered for 7 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 20673361

Group type: EXPERIMENTAL
Intervention: Cervical insufficiency group (CI)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 18343637

Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii La1 (La1)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Cranberry juice/heat-killed La1 (CB)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Cranberry juice/Lactobacillus johnsonii La1 (CB/La1)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo juice/heat-killed La1 (control)
Number of subjects: 295
Study: 16182023

Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude chiropractic adjustments (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mechanical-force, manually-assisted chiropractic adjustments (group 2)
Number of subjects: 60
Study: 12879833

Group type: EXPERIMENTAL
Intervention: Recruitment via general practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recruitment via local newspaper article
Number of subjects: 0
Study: 10319076

Group type: EXPERIMENTAL
Intervention: Aggressive diet and exercise recommendations, lipid-lowering drugs according to NCEP guidelines
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Dietary compliance
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Weekly exercise
Number of subjects: 152
Study: 8732324

Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine combined with enalapril and/or hydrochlorothiazide)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 421
Study: 8517385

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg, titrated to a maximum of 40 mg/day
Number of subjects: 550

Group type: COMPARATOR
Intervention: Pravastatin 10 mg, titrated to a maximum of 40 mg/day
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Simvastatin and Pravastatin
Number of subjects: 550
Study: 3127574

Group type: EXPERIMENTAL
Intervention: Natural surfactant preparation consisting of lipids extracted from calf lung lavage
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no surfactant)
Number of subjects: 72
Study: 30024827

Group type: EXPERIMENTAL
Intervention: Zoster Virus Live (ZVL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26860807

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) as maintenance therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Best supporting care (BSC)
Number of subjects: 106
Study: 25130788

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide levels in AKI group
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: D-dimer levels in AKI group
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels in AKI group
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Endothelial cell-selective adhesion molecule levels in AKI group
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Adiponectin levels in AKI group
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Von Willebrand factor levels in AKI group
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Cystatin C levels in AKI group
Number of subjects: 390

Group type: COMPARATOR
Intervention: Chemokine (C-C motif) ligand 23 levels in no-AKI group
Number of subjects: 390
Study: 23233721

Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 414

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 414
Study: 21810269

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 60
Study: 19342701

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (300 microg/d as high-Se yeast)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 16428753

Group type: EXPERIMENTAL
Intervention: ACAM2010 vaccine (5 x 10^9 CFU)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study: 15571534

Group type: EXPERIMENTAL
Intervention: Routine glove use by healthcare workers for all residents without contact-isolation precautions
Number of subjects: 667

Group type: COMPARATOR
Intervention: Contact-isolation precautions for residents with vancomycin-resistant enterococci or methicillin-resistant Staphylococcus aureus
Number of subjects: 667
Study: 11264331

Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 89
Study: 10446037

Group type: EXPERIMENTAL
Intervention: 400 mg/day of alpha-tocopherol (n = 27)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 39
Study: 8005274

Group type: EXPERIMENTAL
Intervention: Episodic progesterone (P) administration (12.5 mg IM on days 2 and 7) during the artificial follicular phase (Group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Episodic progesterone (P) administration (6.25 mg on days 3, 4, and 5) during the artificial follicular phase (Group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard preparatory cycles without P supplementation (Group C)
Number of subjects: 32
Study: 2643039

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 673

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 673
Study: 4568265

Group type: EXPERIMENTAL
Intervention: Steroids for 7 to 8 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 135
Study: 29393061

Group type: EXPERIMENTAL
Intervention: Automated repetitive simulated annealing molecular dynamics (AR‐SAMD) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dead End Elimination cum Monte Carlo based optimization tool
Number of subjects: 0
Study: 26253032

Group type: EXPERIMENTAL
Intervention: PPC-M1 paired-pulse stimulation at 80% RMT preconditioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPC-PMv-M1 stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PMv-M1 paired-pulse stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPC-M1 paired-pulse stimulation
Number of subjects: 0
Study: 24382580

Group type: EXPERIMENTAL
Intervention: Robotic therapy (ARMin exoskeleton robot)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 77
Study: 23477205

Group type: EXPERIMENTAL
Intervention: Dairy products (932 mg Ca; n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Calcium citrate tablets (1000 mg calcium/day; n = 18)
Number of subjects: 37
Study: 20942666

Group type: EXPERIMENTAL
Intervention: Nevirapine plus tenofovir–emtricitabine
Number of subjects: 241

Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir plus tenofovir–emtricitabine
Number of subjects: 241
Study: 18070045

Group type: EXPERIMENTAL
Intervention: Oxycodone controlled release (Oxy-CR), 5-10 mg, q12 h/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo, q12 h/day
Number of subjects: 116
Study: 16152994

Group type: EXPERIMENTAL
Intervention: Ultrasound guided IJVC insertion (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blind IJVC insertion (group A)
Number of subjects: 60
Study: 14657879

Group type: EXPERIMENTAL
Intervention: Fish oil (3.7 g n‐3 PUFAs per day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 10206045

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Er:YAG laser treatment
Number of subjects: 21
Study: 2164204

Group type: EXPERIMENTAL
Intervention: Polychemotherapy combined with beta‐ and gamma‐interferon
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polychemotherapy without interferon (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Polychemotherapy with interferon
Number of subjects: 40
Study: 350263

Group type: EXPERIMENTAL
Intervention: Topical atenolol (2% 3 times a day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical pilocarpine (2% 3 times a day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of 2% pilocarpine and 2% atenolol administered 15 minutes apart (3 times a day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8